{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Disease Control Rate (DCR) is the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","groups":[{"description":"Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.","id":"OG000","title":"10 mg LY3435151"}],"populationDescription":"Zero participants were analyzed. The study was terminated early and no data was collected.","reportingStatus":"POSTED","timeFrame":"Baseline through Measured Progressive Disease (Up to 4 Months)","title":"Disease Control Rate (DCR): Percentage of Participants With a Best Overall Response of CR, PR, and Stable Disease","type":"SECONDARY"}